Two Playbooks in Large-Molecule CDMO: WuXi Buys Capacity Counter-Cyclically While Lonza/Catalent Divest to Refocus

In 2026, with domestic biotech funding cold and legacy Western CDMOs retreating, top players are moving in opposite directions — WuXi turning "M&A + guaranteed orders" into a capacity harvester, while Lonza and Catalent use "divestment + refocusing" as a margin-repair playbook.

The 2026 large-molecule CDMO market shows a rare regional divergence: with domestic primary-market assets cheap, WuXi entities are acquiring ready-made GMP capacity and filling it with related-party orders; legacy Western CDMOs are divesting non-core assets and concentrating on high-margin businesses. Both, however, are betting on the same long-term logic — biopharma outsourcing penetration climbing toward 65%.

WuXi's approach can be summarized as an "acquire — integrate — feed guaranteed orders — ramp with small batches" loop. In January 2026, WuXi XDC made a ~HK$3.09B cash tender offer for over 60% of TOT Biopharma (Dongyao), the core asset being an integrated antibody + ADC drug substance + drug product plant in Suzhou exceeding 20,000 L — precisely the commercial-grade capacity scarcest in ADC CDMO. After taking control, WuXi XDC signed a three-year stepped guaranteed CDMO agreement worth nearly RMB 770M in total for 2026–2028, while WuXi Biologics placed small batches to validate the quality system.

August's Transcenta deal followed the same pattern: RMB 190M for a Hangzhou site with RMB 457M book value, buying hardware + contracts + designated staff only. Through this series of deals, WuXi Biologics' manufacturing capacity pool has grown to ~580,000 L. With 28 PPQ projects completed in 2025 (+75% YoY) and 34 planned for 2026, the company is expected to enter a concentrated commercial-approval release inflection from H2 2026 into 2027.

Meanwhile, Lonza and Catalent are on a "margin repair" path: divesting inefficient capacity while focusing on advantaged modalities. Lonza delivered a standout H1 2026 for Advanced Synthesis — CER sales +27.7% and a 48.1% CORE EBITDA margin — while precisely adding to ADC-related assets in Visp and Stein. What shrinks is the perimeter; what grows is the direction.

For industry watchers, both routes rest on the same conviction: biopharma outsourcing penetration has a decade or more of upside, and the window belongs to players with both capacity and the order conversion to fill it. China's CXDMO cost-and-speed edge, amplified by the M&A window, is reshaping the global large-molecule CDMO competitive landscape.